Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome

Xonia Carvajal-Vergara, Ana Sevilla, Sunita L. Dsouza, Yen Sin Ang, Christoph Schaniel, Dung Fang Lee, Lei Yang, Aaron D. Kaplan, Eric D. Adler, Roye Rozov, Yongchao Ge, Ninette Cohen, Lisa J. Edelmann, Betty Chang, Avinash Waghray, Jie Su, Sherly Pardo, Klaske D. Lichtenbelt, Marco Tartaglia, Bruce D. GelbIhor R. Lemischka

Research output: Contribution to journalArticle

Abstract

The generation of reprogrammed induced pluripotent stem cells (iPSCs) from patients with defined genetic disorders holds the promise of increased understanding of the aetiologies of complex diseases and may also facilitate the development of novel therapeutic interventions. We have generated iPSCs from patients with LEOPARD syndrome (an acronym formed from its main features; that is, lentigines, electrocardiographic abnormalities, ocular hypertelorism, pulmonary valve stenosis, abnormal genitalia, retardation of growth and deafness), an autosomal-dominant developmental disorder belonging to a relatively prevalent class of inherited RAS-mitogen-activated protein kinase signalling diseases, which also includes Noonan syndrome, with pleomorphic effects on several tissues and organ systems. The patient-derived cells have a mutation in the PTPN11 gene, which encodes the SHP2 phosphatase. The iPSCs have been extensively characterized and produce multiple differentiated cell lineages. A major disease phenotype in patients with LEOPARD syndrome is hypertrophic cardiomyopathy. We show that in vitro-derived cardiomyocytes from LEOPARD syndrome iPSCs are larger, have a higher degree of sarcomeric organization and preferential localization of NFATC4 in the nucleus when compared with cardiomyocytes derived from human embryonic stem cells or wild-type iPSCs derived from a healthy brother of one of the LEOPARD syndrome patients. These features correlate with a potential hypertrophic state. We also provide molecular insights into signalling pathways that may promote the disease phenotype.

Original languageEnglish
Pages (from-to)808-812
Number of pages5
JournalNature
Volume465
Issue number7299
DOIs
Publication statusPublished - Jun 10 2010

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome'. Together they form a unique fingerprint.

  • Cite this

    Carvajal-Vergara, X., Sevilla, A., Dsouza, S. L., Ang, Y. S., Schaniel, C., Lee, D. F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., Ge, Y., Cohen, N., Edelmann, L. J., Chang, B., Waghray, A., Su, J., Pardo, S., Lichtenbelt, K. D., Tartaglia, M., ... Lemischka, I. R. (2010). Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature, 465(7299), 808-812. https://doi.org/10.1038/nature09005